Bolt Biotherapeut…
USUSDBolt Biotherapeutics (US:BOLT) — Biotechnology: Pharmaceutical Preparations. Liczba giełd, na których notowane są akcje spółki: 1. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.
O firmie
- Strona
- boltbio.com
- Relacje inwestorskie
- investors.boltbio.com/
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siedziba
- REDWOOD CITY, United States
- Prezes
- William P. Quinn
- Pracownicy
- 23
- Akcje w obrocie
- Free float
- 1.62 mln
- Kapitalizacja rynkowa
- 7.92 mln USD
- Insiderzy
- 3.47%
- Inwestorzy instytucjonalni
- 27.92%
- Branża (SIC)
- Pharmaceutical Preparations
- FCF
- −31.5 mln USD
- Dług
- 0
- Zyski i FCF — za 12 miesięcy do 30.06.2026 roku (najnowszy raport firmy).
Opis
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Giełdy i tickery
| Giełda | Ticker | Waluta | Cena | Typ |
|---|---|---|---|---|
| US USA Stocks | BOLT | USD | 4.11 +12.60% | akcje zwykłe |
Wiadomości w tym tygodniu
Brak jeszcze wiadomości ze strony spółki.
Najwięksi akcjonariusze
| Posiadacz | Udział | Akcje | Data raportu |
|---|---|---|---|
| Sofinnova Investments, I… | 7.15% | 137 721 | 2026-06-30 |
| Renaissance Technologies… | 5.12% | 98 625 | 2026-06-30 |
| Vivo Capital, LLC | 3.76% | 72 414 | 2026-06-30 |
| Citadel Advisors Llc | 2.95% | 56 903 | 2026-06-30 |
| T3 Companies, LLC | 1.97% | 38 000 | 2026-06-30 |
| Board Of Trustees Of The… | 1.87% | 35 977 | 2026-06-30 |
| Pfizer Inc | 1.63% | 31 305 | 2026-06-30 |
| Lynx1 Capital Management… | 1.6% | 30 800 | 2026-06-30 |
| Nano Cap New Millennium… | 1.43% | 27 500 | 2026-06-30 |
| QUINN WILLIAM P (Chief E… | ≈1.32% | 25 384 | 2026-09-18 |
| Geode Capital Management… | 0.99% | 19 119 | 2026-06-30 |
| YONEHIRO GRANT (Chief Op… | ≈0.9% | 17 269 | 2026-09-18 |
| NEMEC SARAH (Officer) | ≈0.89% | 17 082 | 2026-09-18 |
| Fidelity Concord Street… | 0.39% | 7 506 | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.37% | 7 060 | 2026-06-30 |
| Fidelity Concord Street… | 0.28% | 5 348 | 2026-07-31 |
| Fidelity Concord Street… | 0.09% | 1 699 | 2026-07-31 |
| Master Investment Portfo… | 0% | 89 | 2026-06-30 |
| Guggenheim Active Alloca… | 0% | 6 | 2026-05-31 |